Marlborough racing tips and best bets for today's races

Marlborough
·2 min read
Marlborough racing tips and best bets for today's races
Marlborough racing tips and best bets for today's races

Following today’s racing tips? In need of some guidance? Or just fancy a flutter?

Each day Marlborough brings you the best bets from every race at every racecourse around the country.

From the bright lights of the Cheltenham Festival and Glorious Goodwood to a low-key evening meeting at Chelmsford City, we have all your racing tips and best bets covered. Meanwhile, you can get the latest betting offers and free bets from the top bookmakers here.

Looking for a daily racing nap? Marlborough will indicate his top tip for the day in traditional style, with his other notable selection highlighted with "NB".

So come back every morning for Marlborough's daily selection. Note, tomorrow's tips will appear towards the bottom of the page. Good luck!

Thursday, January 26

Southwell

12.25 Infinitive
1.00 Soames Forsyte
1.35 Mohatu NAP
2.10 Witch Hunter
2.45 Flower Desert
3.20 Lord Paramount
3.50 Stroxx

Wetherby

12.50 Court At Slip
1.25 Highland Frolic
2.00 Blue Shark
2.35 Iron Bridge
3.10 Etalon
3.40 Stanley Stanley
4.15 Jet Legs

Newcastle

4.00 Skye Breeze
4.30 Run Teddy Run
5.00 Comedian Leader
5.30 Nwaira
6.00 Atrafan
6.30 Mrs Bagerran
7.00 Primo
7.30 Emperor Spirit NB

  • Whistler Nap: Alafdhal, 23.20 Southwell

  • Marlborough Nap: Mohatu, 1.35 Southwell

Friday, January 27

Lingfield

12.45 Come On Girl
1.15 San Juan
1.45 Colors Of Freedom
2.20 Vega Sicilia
2.50 Hot Day
3.25 First Sight
3.55 Mick’s Spirit

Huntingdon

12.55 Trapista
1.25 Ace Rothstein
1.55 Born At Midnight
2.30 Shandancer
3.00 Zambella
3.35 Hector Javilex
4.10 Strong Belle

Doncaster

1.05 Dickens
1.35 William Cody
2.05 Gaelic Park
2.40 Greyval
3.15 Mackenburg NB
3.45 Starlyte
4.20 Patient Dream

Wolverhampton

5.15 Typewritten
5.45 Trusty Scout
6.15 Mountain Song
6.45 Starshiba
7.15 Breezyandbright
7.45 Six Strings
8.15 War In Heaven NAP

  • Whistler Nap: Hands Off 2.05 Doncaster

  • Marlborough Nap: War In Heaven, 8.15 Wolverhampton

Latest Stories

  • Mia Goth Says Oscars Is 'Very Political' After Nope and Pearl Snubs: 'A Change is Necessary'

    Nominations for the 95th Academy Awards on March 12 were announced Tuesday morning

  • Hearing set on competency of Colorado store shooting suspect

    A judge is scheduled to hold a hearing Friday to discuss whether a man charged with killing 10 people at a Colorado supermarket nearly two years ago is mentally competent to stand trial. Court proceedings against Ahmad Al Aliwi Alissa, 23, have been paused for more than a year after Judge Ingrid Bakke found him to be mentally incompetent in December 2021 and sent him to the state mental hospital for treatment. Brief hearings are held periodically to check whether doctors believe Alissa is competent, meaning he is able to understand legal proceedings and work with his lawyers to defend himself.

  • Texas death row inmates sue state over ‘brutal’ solitary confinement conditions

    Class action lawsuit alleges prison authorities are inflicting ‘cruel and unusual punishment’ in breach of constitutional rights

  • Uber and Lyft in New York required to be zero-emission by 2030, officials say

    Mayor Eric Adams announced the initiative was part of the ‘Working People’s Agenda’ at his second state of the city address

  • Clippers extend win streak to 4 with 138-100 rout of Spurs

    Paul George scored 35 points, Kawhi Leonard added 27 and the Los Angeles Clippers extended their winning streak to a season-high four games with a 138-100 rout of the reeling San Antonio Spurs on Thursday night. It was the fifth time this season George has had at least 35 points. George was 14 of 19 from the field, including 5 of 8 from beyond the arc as the Clippers posted their largest winning margin since 2021.

  • Adam Schiff running for Senate in California, joining crowded 2024 primary

    WASHINGTON — Rep. Adam Schiff, D-Calif., announced Thursday he's running for Senate in 2024, joining what's expected to be a crowded Democratic primary race for the seat held by Dianne Feinstein.

  • My first boss: Dana Aleff, CEO and co-founder of Circonomit

    Dana Aleff learnt the art of being able to talk less, observe and watch employees to see what their skills are from her time in the Australian Outback.

  • Winter sports results for 2022-23

    Here's a daily recap of local high school sports.

  • A Key Inflation Report Lands Today. How It Could Help the Fed and the Stock Market.

    The PCE price index is set to show that inflation continued its downward trend in December. Still, Fed officials say fighting rising prices remains a priority and more rate hikes are coming.

  • BioSenic appoints Yves Sagot as Independent Director

    REGULATED INFORMATION Mont-Saint-Guibert, Belgium, January 27, 2023, 7am CET – BioSenic (Euronext Brussels and Paris: BIOS), the clinical stage company specializing in serious autoimmune / inflammatory diseases and cell repair, today announces the appointment of Yves Sagot as a Member of the Board and Independent Director. Yves Sagot has been appointed to the BioSenic Board for his experience and achievements for Relief Therapeutics SA and a number of specific aspects that mirror recent BioSenic

  • J:COM Deploys Qwilt’s Open Caching Solution to Deliver Superior Digital Experiences Across Japan

    REDWOOD CITY, Calif., January 27, 2023--Qwilt today announced that J:COM, Japan’s leading cable broadband and multi-channel video provider, has transformed its video delivery network using Qwilt’s Open Caching solution, boosting its network capacity and enhancing the quality of live streaming, VoD and media applications delivered throughout its network. The deployment brings streaming content closer to J:COM’s 5.62 million subscribing households than ever before, enabling a superior over-the-top

  • argenx Receives Notification of PDUFA Date Extension for SC Efgartigimod

    January 27, 2023 Amsterdam, the Netherlands — argenx (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has extended the review of the Biologics License Application (BLA) for subcutaneous (SC) efgartigimod (1000mg efgartigimod-PH20) for the treatment of adult patients with generalized myasthenia gravis (gMG) to June 20, 2023. The FDA notified

  • Press Release: Dupixent® (dupilumab) recommended for expanded EU approval by the CHMP to treat children as young as six months old with severe atopic dermatitis

    Dupixent® (dupilumab) recommended for expanded EU approval by the CHMP to treat children as young as six months old with severe atopic dermatitis If approved, Dupixent would be the first and only targeted medicine in the EU for these young childrenRecommendation based on a Phase 3 trial in children 6 months to 5 years old showing Dupixent improved skin clearance, reduced overall disease severity and improved health-related quality of lifeIn Europe, about 80,000 children aged 6 months to 5 years

  • Landlords now demanding record £3,000 rent in London – and prices could rise further

    Landlords are asking for a record high rent of £1,172 per month, according to property portal Rightmove, as experts warn rents will keep on rising.

  • Signify reports full-year sales of EUR 7.5 billion, operational profitability of 10.1% and a free cash flow of EUR 445 million

    Press Release January 27, 2023 Signify reports full-year sales of EUR 7.5 billion, operational profitability of 10.1% and a free cash flow of EUR 445 million Full year 20221 Signify's installed base of connected light points increased from 96 million at YE 21 to 114 million at YE 22Sales of EUR 7,514 million; nominal sales increase of 9.5% and CSG of 1.2%LED-based sales represented 83% of total sales (FY 21: 83%)Adj. EBITA margin of 10.1% (FY 21: 11.6%)Net income of EUR 532 million (FY 21: EUR 4

  • Ipsen Receives CHMP Negative Opinion for Palovarotene as a Treatment for Fibrodysplasia Ossificans Progressiva in E.U.

    PARIS, January 27, 2023--Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended not to grant marketing authorization for investigational palovarotene as a treatment for the ultra-rare bone disease, fibrodysplasia ossificans progressiva (FOP). In the E.U. there are currently only symptomatic treatments for FOP, which do not reduce the formation of extra-skeletal bone i

  • NORBIT - NOK 150 million order received for On-Board Units

    Trondheim, 27 January 2023: Reference is made to the stock exchange notice dated 2 January 2023 where NORBIT announced that segment Connectivity had received confirmation from an existing undisclosed European customer of a significant volume increase of On-Board Units, pending final negotiations on commercial terms. Today, NORBIT is pleased to announce that the parties have entered into an agreement and NORBIT has received the order for approximately NOK 150 million. The order received is for de

  • Dupixent® (dupilumab) Recommended for Expanded EU Approval by the CHMP to Treat Children as Young as Six Months Old with Severe Atopic Dermatitis

    If approved, Dupixent would be the first and only targeted medicine in the EU for these young children Recommendation based on a Phase 3 trial in children 6 months to 5 years old showing Dupixent improved skin clearance, reduced overall disease severity and improved health-related quality of life In Europe, about 80,000 children aged 6 months to 5 years with uncontrolled severe atopic dermatitis are candidates for systemic therapy TARRYTOWN, N.Y. and PARIS, Jan. 27, 2023 (GLOBE NEWSWIRE) -- Rege

  • Cryptoqueen: Has the missing fugitive reappeared?

    The Kensington house of Romanian crypto scammer on the FBI's most-wanted list, Ruja Ignatova, mysteriously goes up for sale

  • Bharat Biotech: India launches its first nasal Covid vaccine

    The vaccine's makers say it is effective in preventing infection and transmission of the disease.